Charles Schwab’s Allogene Therapeutics ALLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.73M | Buy |
2,274,363
+877,830
| +63% | +$1.93M | ﹤0.01% | 2510 |
|
|
2026
Q1 | $3.41M | Buy |
1,396,533
+40,724
| +3% | +$81.6K | ﹤0.01% | 2559 |
|
|
2025
Q4 | $1.86M | Buy |
1,355,809
+190,529
| +16% | +$251K | ﹤0.01% | 2773 |
|
|
2025
Q3 | $1.44M | Sell |
1,165,280
-67,255
| -5% | -$80.2K | ﹤0.01% | 2838 |
|
|
2025
Q2 | $1.39M | Buy |
1,232,535
+76,691
| +7% | +$102K | ﹤0.01% | 2787 |
|
|
2025
Q1 | $1.69M | Sell |
1,155,844
-32,994
| -3% | -$62.2K | ﹤0.01% | 2664 |
|
|
2024
Q4 | $2.53M | Buy |
1,188,838
+9,990
| +0.8% | +$24.6K | ﹤0.01% | 2606 |
|
|
2024
Q3 | $3.3M | Buy |
1,178,848
+447
| +0% | +$1.19K | ﹤0.01% | 2555 |
|
|
2024
Q2 | $2.75M | Buy |
1,178,401
+319,925
| +37% | +$944K | ﹤0.01% | 2591 |
|
|
2024
Q1 | $3.84M | Buy |
858,476
+125,641
| +17% | +$524K | ﹤0.01% | 2385 |
|
|
2023
Q4 | $2.35M | Sell |
732,835
-48,493
| -6% | -$138K | ﹤0.01% | 2565 |
|
|
2023
Q3 | $2.48M | Buy |
781,328
+115,997
| +17% | +$508K | ﹤0.01% | 2538 |
|
|
2023
Q2 | $3.31M | Buy |
665,331
+15,046
| +2% | +$81.4K | ﹤0.01% | 2391 |
|
|
2023
Q1 | $3.21M | Buy |
650,285
+1,490
| +0.2% | +$9.56K | ﹤0.01% | 2386 |
|
|
2022
Q4 | $4.08M | Buy |
648,795
+13,340
| +2% | +$123K | ﹤0.01% | 2316 |
|
|
2022
Q3 | $6.86M | Buy |
635,455
+91,346
| +17% | +$1.24M | ﹤0.01% | 2048 |
|
|
2022
Q2 | $6.2M | Buy |
544,109
+13,450
| +3% | +$119K | ﹤0.01% | 2097 |
|
|
2022
Q1 | $4.83M | Sell |
530,659
-6,386
| -1% | -$66.5K | ﹤0.01% | 2298 |
|
|
2021
Q4 | $8.01M | Buy |
537,045
+6,049
| +1% | +$107K | ﹤0.01% | 2117 |
|
|
2021
Q3 | $13.6M | Sell |
530,996
-103,373
| -16% | -$2.45M | ﹤0.01% | 1832 |
|
|
2021
Q2 | $16.5M | Buy |
634,369
+71,315
| +13% | +$2.03M | 0.01% | 1720 |
|
|
2021
Q1 | $19.9M | Buy |
563,054
+13,047
| +2% | +$440K | 0.01% | 1539 |
|
|
2020
Q4 | $13.9M | Buy |
550,007
+10,124
| +2% | +$330K | 0.01% | 1659 |
|
|
2020
Q3 | $20.4M | Buy |
539,883
+9,017
| +2% | +$340K | 0.01% | 1191 |
|
|
2020
Q2 | $22.7M | Buy |
530,866
+128,713
| +32% | +$4.65M | 0.01% | 1081 |
|
|
2020
Q1 | $7.82M | Buy |
402,153
+6,706
| +2% | +$160K | ﹤0.01% | 1602 |
|
|
2019
Q4 | $10.3M | Buy |
395,447
+8,627
| +2% | +$238K | 0.01% | 1656 |
|
|
2019
Q3 | $10.5M | Buy |
386,820
+195,477
| +102% | +$5.57M | 0.01% | 1579 |
|
|
2019
Q2 | $5.14M | Buy |
191,343
+38,579
| +25% | +$1.07M | ﹤0.01% | 1960 |
|
|
2019
Q1 | $4.42M | Buy |
152,764
+8,637
| +6% | +$251K | ﹤0.01% | 2028 |
|
|
2018
Q4 | $3.88M | Buy |
+144,127
| New | +$3.83M | ﹤0.01% | 2031 |
|
Other funds holding ALLO
P
FLSM
TGA
SCM
Charles Schwab's ALLO Position: Q2 2026 in Review
Charles Schwab increased its Allogene Therapeutics (ALLO) stake by 63% in Q2 2026, buying an estimated $1.93M and bringing the position to 2,274,363 shares worth $4.73M. The position accounts for ﹤0.01% of the portfolio, ranked #2510.
Charles Schwab first reported a position in ALLO in Q4 2018 and has held it in 31 quarters since. The position peaked at $22.7M in Q2 2020. 208 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.
- Charles Schwab held 2,274,363 shares of Allogene Therapeutics worth $4.73M as of Q2 2026.
- Charles Schwab bought 877,830 Allogene Therapeutics shares in Q2 2026, an estimated $1.93M.
- Allogene Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2510 holding.
- Charles Schwab first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 31 quarters since.
- Charles Schwab's Allogene Therapeutics position peaked at $22.7M in Q2 2020.
- 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.